A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals

Active
No
Status
Closed
Release Date
August 25th, 2023
Open Date
August 25th, 2023
Due Date(s)
November 14th, 2023
Close Date
November 14th, 2023
Topic No.
NIH/NCI 462

Topic

Organ-on-Chip for Preclinical and Translational Radiobiological Studies

Agency

Department of Health and Human ServicesNational Institutes of Health

Program

Type: SBIRPhase: BOTHYear: 2023

Summary

The Department of Health and Human Services, specifically the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC), are seeking proposals for Small Business Innovation Research (SBIR) contract proposals. The specific topic of the solicitation is "Organ-on-Chip for Preclinical and Translational Radiobiological Studies". The technology being solicited is the development and integration of advanced Organ-on-Chip (OoC) systems into cancer treatment development and translational pipelines in radiobiology and drug radiation combination studies. OoC systems are microfluidic devices that mimic tissue and tumor microenvironments, providing physiologically and clinically relevant models for preclinical radiobiological research. These models have the potential to improve the prediction of drug-radiation combination efficacy and toxicities, determine the relative biological effectiveness of proton therapy, and reduce the cost of research by improving preclinical research quality and potentially reducing animal use. Fast-Track proposals and Direct-to-Phase II proposals will be accepted. The anticipated number of awards is 2-3. The budget for Phase I is up to $400,000 for up to 12 months, and the budget for Phase II is up to $2,000,000 for up to 2 years. Proposals that exceed the budget or project duration listed may not be funded. Overall, this solicitation aims to accelerate the development and validation of advanced OoCs for preclinical and translational radiobiological studies, with the potential to impact cancer treatment development and other areas of cancer research.

Description

Fast-Track proposals will be accepted. Direct-to-Phase II proposals will be accepted. Number of anticipated awards: 2-3 Budget (total costs, per award): Phase I: up to $400,000 for up to 12 months Phase II: up to $2,000,000 for up to 2 years PROPOSALS THAT EXCEED THE BUDGET OR PROJECT DURATION LISTED ABOVE MAY NOT BE FUNDED. Summary 2D monolayer cultures fail to recapitulate the totality of the tumor microenvironments. More complex cancer in vitro models have been developed, but they still lack organ-level structures, fluid flows, and mechanobiological cues that cells experience in vivo. Therefore, physiologically and clinically relevant reproducible models that mimic tissue and tumor microenvironments are urgently needed to improve preclinical radiobiological research. Such model systems could impact several areas, such as the ability to predict efficacy and toxicities of drug-radiation combinations, to determine the relative biological effectiveness of proton therapy, etc. These models are also applicable in other areas of cancer research. Generally, they will reduce the cost of research by improving the preclinical research quality and potentially reducing animal use in research. Microfluidics (materials and techniques) have potential applications in radiobiology, and commonly used siliconebased compounds, such as polydimethylsiloxane (PDMS), have already been tested and found resistant to radiation-induced brittleness and aging and have demonstrated required stability and water equivalency. Lab-on-chip (LOC) microfluidic and “tissue mimetic” technologies have evolved into advanced Organ-on-Chips (OoC). OoC systems containing perfused hollow microchannels populated with living cells have the ability of multiplexed drug testing and may be applied to many radiobiological studies. OoC technologies are already at a higher technological level of maturity. Further development and validation of OoC guided by its intended context of use for translational radiobiological studies are necessary. This SBIR contract mechanism accelerates further development and integration of advanced OoCs into cancer treatment development and translational pipelines in radiobiology and drug radiation combination studies.